ClearPoint Neuro, Inc. Q3 FY2026 earnings call

• Biologics and Drug Delivery: Progressing toward establishing ClearPoint as the gold standard for cell and gene therapy delivery. Supporting partner Unicure’s BLA submission for AMT130 (Huntington’s disease) with device documentation on file; expect potential companion 510K submission upon FDA acceptance. Expanding ClearPoint Advanced Laboratories in Torrey Pines, CA, adding PET/SPECT capabilities and hiring talent to support over 60 active biopharma partners, including multiple Phase III trials initiating in 2027.
• Neurosurgery Navigation: Achieved record capital sales quarter, driven by demand from academic centers preparing for drug delivery trials and adoption of the ICT operating room solution for routine DBS/biopsy cases. Continued development of a dedicated cranial robotic platform designed specifically for multi-trajectory infusions, distinct from broader neurosurgical robots.
• Laser Therapy and Access: Partnered with Dartmouth Health on an NCI R1 grant to advance MR-guided laser therapy for spinal metastases using the PRISM system. Identified SpineLIT as a significant long-term opportunity addressing >10,000 patients globally, potentially offering a first-mover advantage in spinal tumor ablation.
• Intracranial Fluid Management: Aeroflow (Eraflow) positioned for advancement in neurocritical care. Targeting five key milestones in 2027, including launch of Shoreline software, DART catheter, next-gen tunneling catheter, ARCH trial results, and pursuit of on-label FDA indication for subdural hematoma.
• Financial Integration: Operating expenses grew 23% while revenue grew 36%, demonstrating scalability. Raised $22 million via ATM facility to fund Cal startup costs and field team expansion. Ended Q3 with $46.2 million in cash.

Total revenue increased by 36% year-over-year to $12.1 million in Q3 2026, compared to $8.9 million in Q3 2025. The growth was driven by three segments: Biologics and drug delivery reached $4.9 million (up 11% from $4.4 million), representing approximately 40.7% of total revenue; Neurosurgery navigation grew significantly to $5.4 million (up 59% from $3.4 million), accounting for roughly 44.6% of revenue, largely due to the newly acquired Aeroflow product; Capital equipment and software rose to $1.7 million (up 68% from $1.0 million), contributing about 14.1% of revenue. Gross margin decreased to 58% from 63%, primarily due to overhead costs at the new California facility and amortization of acquired intangible assets.

• Maintained expectation of mid-teens year-over-year revenue growth for 2027 base business.
• Implied Q4 2026 revenue midpoint of $49 million, reflecting strong momentum across capital equipment, disposables, and CAL services.
• No official full-year guidance provided yet; management indicated they will reassess outlook in Fall 2026 following regulatory updates on AMT130 and initiation of Phase III trials.

• Regulatory Delays: Potential delays in FDA review of Unicure’s BLA or ClearPoint’s companion 510K could impact commercialization timelines.
• Clinical Trial Execution: Scaling from small Phase I studies to large Phase III trials (up to 200 patients/20 sites) requires significant clinical infrastructure and staffing readiness.
• Competitive Landscape: Risk of underutilization if hospitals adopt competing robotics solutions not optimized for cranial workflows.
• Cash Burn: Front-loaded investments in CAL facility, robotics, and focused ultrasound require sustained capital; operational burn remains a concern despite recent cost controls.

Q: Analyst asked for prioritization of upcoming partner catalysts and visibility into front-loaded field investments.

A: CEO highlighted Unicure’s AMT130 BLA decision as the near-term primary catalyst, expecting FDA acceptance within months and potential approval in mid-to-late 2027. Emphasized that regardless of approval timing, the clinical team is being scaled now to support parallel confirmatory trials and other Phase III initiations. Regarding investments, noted that pre-clinical monetization is possible via CAL services, and that robotics/focused ultrasound investments are critical to enable scalable, non-MRI-suite procedures, unlocking value before FDA clearance.

Q: Analyst requested clarity on cash burn trajectory and revenue per case for the new SpineLIT opportunity.

A: CFO indicated that while CapEx related to CAL will increase burn slightly in the next 12 months, operational burn is expected to decline over the next 4-6 quarters as revenue outpaces OPEX growth. CEO estimated SpineLIT revenue at $13,000-$20,000 per procedure (~$15k average). Regulatory pathway remains undefined but may leverage existing neurosurgery label or require new indications based on trial data.

Q: Analyst questioned the achievability of the implied Q4 2026 revenue step-up and 2027 growth expectations.

A: CEO attributed Q4 upside to healthy funnels across four capital contributors (navigation, ICT, Prism, Eraflow) and anticipated conversion of new installations into disposable revenue. Confirmed sequential CAL service growth. For 2027, reiterated confidence in mid-teens base growth, pending visibility on Phase III starts and AMT130 regulatory outcomes in the coming months.